Evoke Pharma Stock Price, News & Analysis (NASDAQ:EVOK) $1.26 +0.05 (+4.13%) (As of 11/29/2023 ET) Add Compare Share Share Today's Range$1.24▼$1.2950-Day Range$0.96▼$1.3952-Week Range$0.92▼$5.96Volume7,882 shsAverage Volume23,772 shsMarket Capitalization$4.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media About Evoke Pharma Stock (NASDAQ:EVOK)Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Read More EVOK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVOK Stock News HeadlinesNovember 27, 2023 | finanznachrichten.deEvoke Pharma, Inc.: Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI PatentNovember 26, 2023 | americanbankingnews.comEvoke Pharma (NASDAQ:EVOK) Receives New Coverage from Analysts at StockNews.comNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 14, 2023 | marketwatch.comEvoke Pharma Shares Rise on New Gimoti U.S. PatentNovember 14, 2023 | finance.yahoo.comUnited States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTINovember 10, 2023 | msn.comEvoke Pharma files to sell common stock and warrantsNovember 9, 2023 | benzinga.comEvoke Pharma: Q3 Earnings InsightsNovember 9, 2023 | msn.comEvoke Pharma GAAP EPS of -$0.51, revenue of $1.56MNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 9, 2023 | finance.yahoo.comEvoke Pharma Reports Third Quarter 2023 Financial ResultsNovember 5, 2023 | msn.comWhy Are There So Many Pharma Stories Right Now?October 31, 2023 | finance.yahoo.comEvoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023October 30, 2023 | markets.businessinsider.comEvoke Announces Appointment of Group President Cris MortonOctober 25, 2023 | msn.comREVIEW: ‘Pain Hustlers’ Needs A Higher Dosage Of Fresh IdeasOctober 23, 2023 | markets.businessinsider.com7 Under-the-Radar Growth Stocks Ready to Make a SplashOctober 18, 2023 | finance.yahoo.comEvoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 Annual MeetingSeptember 14, 2023 | finanznachrichten.deEvoke Pharma, Inc.: Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTISeptember 14, 2023 | finance.yahoo.comEvoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®August 15, 2023 | finance.yahoo.comEvoke launches audience intelligence offering to unlock full commercial potential of life sciences brandsAugust 10, 2023 | msn.comEvoke Pharma GAAP EPS of -$0.56 beats by $0.17, revenue of $1.13M beats by $0.03MAugust 10, 2023 | finanznachrichten.deEvoke Pharma, Inc.: Evoke Pharma Reports Second Quarter 2023 Financial ResultsAugust 10, 2023 | finance.yahoo.comEvoke Pharma Reports Second Quarter 2023 Financial ResultsAugust 8, 2023 | msn.comMayo's Aidan O'Shea and fiancée Kristin celebrate engagement in exotic locationAugust 7, 2023 | finance.yahoo.comEvoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) MeetingAugust 3, 2023 | forbes.comThe Psychology Of Color: 5 Ways You Can Use Color To Build Brand IdentityJuly 29, 2023 | msn.comFeeling like a winner: Mayo's Aidan O'Shea pops the questionJuly 25, 2023 | finance.yahoo.comEvoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual MeetingSee More Headlines Receive EVOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2023Today11/29/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/19/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EVOK CUSIPN/A CIK1403708 Webwww.evokepharma.com Phone(858) 345-1494FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,220,000.00 Net Margins-176.93% Pretax Margin-176.93% Return on Equity-517.99% Return on Assets-78.59% Debt Debt-to-Equity Ratio9.29 Current Ratio3.50 Quick Ratio3.27 Sales & Book Value Annual Sales$2.51 million Price / Sales1.69 Cash FlowN/A Price / Cash FlowN/A Book Value($0.26) per share Price / Book-4.88Miscellaneous Outstanding Shares3,340,000Free Float2,949,000Market Cap$4.24 million OptionableNot Optionable Beta0.28 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. David A. Gonyer R.Ph. (Age 59)Co-Founder, CEO & Director Comp: $806.53kMr. Matthew J. D'Onofrio MBA (Age 53)Co-Founder, President, COO, Secretary & Treasurer Comp: $557.11kDr. Marilyn R. Carlson (Age 75)Chief Medical Officer Comp: $518.14kMr. Christopher QuesenberryChief Commercial Officer - Gimoti (TM)Key CompetitorsKiora PharmaceuticalsNASDAQ:KPRXNeuroMetrixNASDAQ:NUROGBSNYSE:GBSAvingerNASDAQ:AVGRNabriva TherapeuticsNASDAQ:NBRVView All Competitors EVOK Stock Analysis - Frequently Asked Questions How have EVOK shares performed in 2023? Evoke Pharma's stock was trading at $2.68 at the beginning of the year. Since then, EVOK shares have decreased by 52.9% and is now trading at $1.2611. View the best growth stocks for 2023 here. Are investors shorting Evoke Pharma? Evoke Pharma saw a increase in short interest in November. As of November 15th, there was short interest totaling 22,500 shares, an increase of 54.1% from the October 31st total of 14,600 shares. Based on an average trading volume of 12,200 shares, the short-interest ratio is currently 1.8 days. Approximately 0.7% of the company's stock are short sold. View Evoke Pharma's Short Interest. When is Evoke Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 19th 2024. View our EVOK earnings forecast. How were Evoke Pharma's earnings last quarter? Evoke Pharma, Inc. (NASDAQ:EVOK) issued its quarterly earnings data on Tuesday, March, 21st. The specialty pharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter. The specialty pharmaceutical company had revenue of $0.80 million for the quarter. Evoke Pharma had a negative net margin of 176.93% and a negative trailing twelve-month return on equity of 517.99%. When did Evoke Pharma's stock split? Evoke Pharma shares reverse split on the morning of Monday, May 23rd 2022. The 1-12 reverse split was announced on Monday, May 23rd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What other stocks do shareholders of Evoke Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evoke Pharma investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Advanced Micro Devices (AMD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD) and Bed Bath & Beyond (BBBY). Who are Evoke Pharma's major shareholders? Evoke Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David A Gonyer and Matthew J D'onofrio. View institutional ownership trends. How do I buy shares of Evoke Pharma? Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:EVOK) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.